Compare Twist Bioscience Corp (TWST) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs VICI Properties Inc — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.42B), while VICI Properties Inc trades at $25.27 (market cap $27.82B). The key difference: VICI Properties Inc is far larger — about 3.3× Twist Bioscience Corp's market cap, and VICI Properties Inc pays a 7.28% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TWST | VICI | |
|---|---|---|
Market Cap | $8.42B | $27.82B |
Sector | Health | Real Estate |
52-Week High | $153.10 | $33.16 |
52-Week Low | $24.16 | $25.23 |
Enterprise Value | $8.35B | $45.38B |
Dividend Yield | — | 7.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
VICI trades at $25.29, down 0.51% today, with a bearish technical signal from moving averages but oversold RSI readings. The stock offers a high dividend yield above 7%, supported by strong profitability margins (net income margin 67.5% in 2025) and a low P/E of 9.79. Recent corporate actions include a dividend increase to $0.46 per share and the appointment of a new independent director, reflecting steady governance.
Outlook remains positive with a consensus price target of $29.29 (16% upside), driven by stable cash flows and REIT income appeal. Risks include earnings volatility (two recent EPS misses) and acquisition yield pressures. Institutional sentiment is bullish (77% buy ratings), but technical weakness near support at $25 requires monitoring for entry opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
